Towards cost-effective strategies for treatment of chronic kidney disease-mineral and bone disorder in Japan

Therapeutic Apheresis and Dialysis

Volumn 13, Issue SUPPL. 1, 2009, Pages

  Komaba, Hirotaka ^a   Moriwaki, Kensuke ^b   Kamae, Isao ^b,c   Fukagawa, Masafumi ^a,d  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease mineral and bone disorder (CKD MBD); Cinacalcet hydrochloride; Cost effectiveness analysis; Cost utility analysis; Health economic evaluation; Vitamin D analog

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CALTAN; CINACALCET; FALECALCITRIOL; LANTHANUM CARBONATE; PARICALCITOL; PHOSBLOCK; REGPARA; SEVELAMER; UNCLASSIFIED DRUG;

CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HUMAN; JAPAN; MORBIDITY; MORTALITY; PARATHYROIDECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL OSTEODYSTROPHY; REVIEW; THERAPY DELAY;

BONE DISEASES, METABOLIC; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 70349336598     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00771.x     Document Type: Review

References (55)

1. Nakai S, Masakane I, Shigematsu T et al. An overview of dialysis treatment in Japan (as of 31 Dec. 2007). J Jpn Soc Dial Ther 2009 42 : 1 45 (In Japanese).
2. Oliver AJ, Ikegami N, Ikeda S. Japan's aging population. Implications for healthcare. Pharmacoeconomics 1997 11 : 306 318.
3. Nakai S, Masakane I, Akiba T et al. Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial 2008 12 : 428 456.
4. Tsukamoto Y, Wang H, Becker G et al. Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. "Current status and perspective of CKD in Asia": diversity and specificity among Asian countries. Clin Exp Nephrol 2009 13 : 247 256.
5. Fukuhara S, Yamazaki C, Hayashino Y et al. The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ 2007 7 : 217 231.
6. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009 24 : 1506 1523.
7. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006 69 : 1945 1953.
8. Rawlins MD. NICE work - providing guidance to the British National Health Service. N Engl J Med 2004 351 : 1383 1385.
9. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med 2005 353 : 1516 1522.
10. American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 2008 148 : 956 961.
11. Steinbrook R. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med. 2008 359 : 1977 1981.
12. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd Edition. New York, NY : Oxford University Press, 2005.
13. Churchill DN, Torrance GW, Taylor DW et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987 10 : 14 20.
14. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998 44 : 215 232.
15. de Wit GA, Merkus MP, Krediet RT et al. Health profiles and health preferences of dialysis patients. Nephrol Dial Transplant 2002 17 : 86 92.
16. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992 45 : 505 512.
17. Molzahn AE, Northcott HC, Hayduk L. Quality of life of patients with end stage renal disease: a structural equation model. Qual Life Res 1996 5 : 426 432.
18. Shiroiwa T, Sung YK, Fukuda T et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ, in press.
19. Winkelmayer WC, Weinstein MC, Mittleman MA et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002 22 : 417 430.
20. Mowatt G, Vale L, Perez J, Wyness L et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technol Assess 2003 7 : 1 174.
21. Lee CP, Chertow GM, Zenios SA. An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard. Value in Health 2009 12 : 80 7.
22. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ 2009 338 : b181.
23. Raftery J. Should NICE's threshold range for cost per QALY be raised? No. BMJ 2009 338 : b185.
24. Manns B, Meltzer D, Taub K et al. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Economics 2003 12 : 949 958.
25. Komaba H, Tanaka M, Fukagawa M. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Intern Med 2008 47 : 989 994.
26. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Battleground: chronic kidney disorders mineral and bone disease - calcium obsession, vitamin d, and binder confusion. Clin J Am Soc Nephrol 2008 3 : 168 173.
27. Huybrechts KF, Caro JJ, London GM. Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney Int 2005 67 : 1532 1538.
28. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int 2007 71 : 312 317.
29. Manns B, Klarenbach S, Lee H et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007 22 : 2867 2878.
30. Taylor MJ, Elgazzar HA, Chaplin S et al. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin 2008 24 : 601 608.
31. Huybrechts KF, Caro JJ, O'Brien JA. Prevention and Management of Hyperphosphatemia with Sevelamer in Canada: Health and Economic Consequences. Value Health (In press).
32. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002 62 : 245 252.
33. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007 72 : 1130 1137.
34. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007 71 : 438 441.
35. Komaba H, Fukagawa M. Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer? Nat Clin Pract Nephrol 2007 3 : 418 419.
36. Brennan A, Akehurst R, Davis S et al. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health 2007 10 : 32 41.
37. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005 100 : c8 19.
38. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 349 : 446 456. (Pubitemid 36910023)
39. Dobrez DG, Mathes A, Amdahl M et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004 19 : 1174 1181.
40. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005 68 : 2823 2828.
41. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006 70 : 771 780.
42. Rosery H, Bergemann R, Marx SE et al. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Investig 2006 26 : 629 638.
43. Gal-Moscovici A, Sprague SM. Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. Clin Drug Investig 2007 27 : 105 113.
44. Nuijten M, Andress DL, Marx SE et al. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin 2009 25 : 1221 1234.
45. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009 24 : 963 972.
46. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 350 : 1516 1525.
47. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005 67 : 760 771.
48. Dong BJ. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 2005 27 : 1725 1751.
49. Garside R, Pitt M, Anderson R et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007 11 (18).
50. Fukagawa M, Yumita S, Akizawa T et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008 23 : 328 335.
51. Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007 2 : 898 905.
52. Narayan R, Perkins RM, Berbano EP et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007 49 : 801 813.
53. Garside R, Pitt M, Anderson R et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007 22 : 1428 1436.
54. Ray JA, Borker R, Barber B et al. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health 2008 11 : 800 808.
55. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003 14 : 3270 3277.